Bai Jie, Xue Yang-Ping, Ye Lei, Yao Jian-Feng, Zhou Chun-Lin, Qian Lin-Sheng, Yang Ren-Chi, Li Hai-Yan, Zhang Hong-Yun, Shao Zong-Hong
Institute of Hematology and Blood Diseases Hospital CAMS & PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):685-8.
To reassess the natural history of polycythemia vera (PV) in Chinese and evaluate the relationship between the incidence of thrombosis, post-polycythaemic myelofibrosis with myeloid metaplasia( PPMM) , leukemia transformation and the therapeutic outcome and prognostic factors.
The clinical manifestations, laboratory parameters and treatment were retrospectively analyzed in 287 patients with PV. Univariate analysis of prognostic factors was performed using Log-rank model and multivariate analysis using COX model in term of the incidence of thrombosis, PPMM, hematologic or non hematologic cancers and mortality.
Of the 287 patients, the median follow-up time was 46 (8-360) months. 208 thromboses were recorded in 115 patients. Twice or more thrombotic events occurred on 59 patients (51.34%). Most of these episodes occurred either at presentation or in the 2 years before diagnosis. Elder patients, prior thrombosis, poor response to therapy were associated with poor prognosis. With these three adverse prognostic factors, the patients could be separated into different risk groups. The incidence of thrombosis was higher in high risk group. 36 patients progressed to PPMM, the median time to PPMM was 80 (7-190) months. Higher WBC count, splenomegaly and treatment with alkylating agent and hydroxy-carbamide (HU) were associated with poor prognosis. 2 cases progressed to AML. 1 to lymphoma and 1 to nonhematologic cancer. 13 patients died, the cause of death was fatal thrombosis in 9 and AML in 2.
The incidence of thromboembolism is higher and the time to myelofibrosis was shorter in Chinese PV patients than in western PV patients. The main factors that influence the survival of PV patients are thromboembolism and leukemia transformation.
重新评估真性红细胞增多症(PV)在中国患者中的自然病程,并评估血栓形成、真性红细胞增多症后骨髓纤维化伴髓外化生(PPMM)、白血病转化的发生率与治疗效果及预后因素之间的关系。
对287例PV患者的临床表现、实验室参数及治疗情况进行回顾性分析。采用Log-rank模型对预后因素进行单因素分析,采用COX模型对血栓形成、PPMM、血液系统或非血液系统癌症的发生率及死亡率进行多因素分析。
287例患者的中位随访时间为46(8 - 360)个月。115例患者发生了208次血栓形成事件。59例患者(51.34%)发生了两次或更多次血栓事件。这些事件大多发生在就诊时或诊断前2年。老年患者、既往有血栓形成、对治疗反应不佳与预后不良相关。有这三个不良预后因素的患者可分为不同风险组。高风险组的血栓形成发生率更高。36例患者进展为PPMM,进展至PPMM的中位时间为80(7 - 190)个月。白细胞计数较高、脾肿大以及使用烷化剂和羟基脲(HU)治疗与预后不良相关。2例进展为急性髓系白血病(AML)。1例进展为淋巴瘤,1例进展为非血液系统癌症。13例患者死亡,9例死于致命性血栓形成,2例死于AML。
中国PV患者的血栓栓塞发生率较高,骨髓纤维化发生时间较西方PV患者短。影响PV患者生存的主要因素是血栓栓塞和白血病转化。